GlobeNewswire

hemCheck approved for trading on Nasdaq First North - Regulatory

Dela

hemCheck approved for trading on Nasdaq First North - Regulatory

This Press Release should not be released or distributed, directly or indirectly, within USA, Canada, Japan, Australia, Hong Kong, Switzerland, Singapore, South Africa, New Zealand or any other jurisdictions where distribution would be subject to legal restrictions.

Nasdaq First North has approved hemCheck Sweden AB's (publ) ('hemCheck' or the 'Company') application for listing of the Company's shares, and subscription option rights of series TO 1, for admission for trading on Nasdaq First North. The first trading day will be 15 March 2017. The ticker symbol for the Company's shares on First North is HEMC, the ticker symbol for the subscription option rights is HEMC TO 1.

hemCheck develops and commercializes a unique product concept (Helge(TM) and READY(TM)) that detects hemolysis in blood samples at the point of care. Nasdaq Stockholm AB has approved hemCheck's application for the Company's shares and subscription option rights (series TO 1) to begin trading on Nasdaq First North. The first day of trading will be March 15, 2017.

hemCheck CEO Annelie Brolinson:
"We're delighted interest in our share issue has been so great. We look forward to begin trading on 15 March. The whole team at hemCheck will continue to keep working hard to meet all our shareholders' expectations. As previously announced we will now finalize our product concept, consisting of Helge(TM) and READY(TM), for CE marking. We can then go full speed ahead with the market launch of our concept, starting in Sweden."

Background
In February hemCheck announced that the company had received over 1900 new shareholders through a new issue of units. Each unit consisted of one share and one subscription option rights of series TO 1. With subscription option rights issued free of charge the subscription price per unit amounted to SEK 6 per share. The issue volume of 28.2 million initially signed to approximately 59 MSEK, a subscription rate equivalent to approx. 209%. As the rights issue was oversubscribed, the Board decided to make full use of an over-allotted issue. The company thus initially raised approx. 30 MSEK prior to listing, and if all share issue costs and / or all outstanding subscription option rights will be used before Q1 2018, the Company will receive an additional 30 MSEK before issue costs.

The ticker symbol for the Company's shares on First North is HEMC, the ticker symbol for subscription option rights is HEMC TO 1.

Conditions for subscription option rights
Possession of a series TO 1 subscription option rights entitles the owner to subscribe for one of the new shares at a price of SEK 6 for a period from 29 January 2018, up to and including 9 February 2018.

Full details on how warrants will be used for subscription of shares in hemCheck will be made available on the Company's website,www.hemcheck.com, and Aktieinvest's website www.aktieinvest.se from 29 January 2018. Full terms and conditions for the warrants of series TO 1 will be detailed in the section Full terms and conditions for the warrants of series TO 1 in the prospectus being prepared for the new share issue, which is available on the Company website.

Advisors
Corpura AB is the financial advisor for the new share issue, and Fredersen Advokatbyrå AB is acting legal advisor. hemCheck's Certified Adviser on Nasdaq First North will be Corpura AB. Aktieinvest FK AB is acting as receiving agent in connection with the rights issue.

About hemCheck
hemCheck Sweden AB (publ) develops and commercializes a unique product concept (HELGE(TM) and READY(TM)) that detects hemolysis in blood samples at the point of care. Hemolysis, or the rupturing of red blood cells, is the most common reason for blood samples being unfit for analysis-which can lead to poorer healthcare, increased risk for patients and higher costs for clinics and society. By detecting hemolysis in blood tests directly, HELGE(TM) can contribute to improved care for patients throughout the world. hemCheck is headquartered in Karlstad, Sweden. hemCheck prepared a prospectus for the issue of new units before its resumption of trading on Nasdaq First North.

Contact
hemCheck Sweden AB (publ)
Annelie Brolinson, CEO
Tel: +46 70 288 0826
E-post: annelie.brolinson@hemcheck.com
Universitetsgatan 2
651 88 Karlstad
www.hemcheck.com

Important information
The information in this press release may not be published, reproduced or distributed in or into the United States, Canada, Japan, Australia, Hong Kong, Switzerland, Singapore, South Africa or New Zealand or any other country or other jurisdiction where such action is not permitted, or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities laws.

No interim units or units have been registered and will not be registered under the United States Securities Act of 1933 (the 'Securities Act') and may not be offered, subscribed to, sold or transferred, directly or indirectly, within the United States, except with the written approval from hemCheck and pursuant to an applicable exemption from the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction of the United states.

This is information which hemCheck is required to disclose according to EU Market Abuse Regulation law. The information was provided by the above contact person's auspices, for publication on 13 March 2017, 1725.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hemcheck Sweden AB via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum